Versluis, J. M.
Hoefsmit, E. P.
Shehwana, H.
Dimitriadis, P.
Sanders, J.
Broeks, A.
Blank, C. U.
Article History
Received: 30 September 2023
Accepted: 14 November 2023
First Online: 27 January 2024
Declarations
:
: PD reported financial interest in Signature Oncology and will receive some possible revenues if the IFNγ signature is being developed as a clinical companion diagnostic. CUB received compensation (all paid to the institute except TRV) for advisory roles for Bristol-Myers Squibb, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures; received research funding (all paid to the institute) from Bristol-Myers Squibb, Novartis, NanoString, and declares stockownership in Immagene BV, where he is co-founder. All remaining authors have declared no conflicts of interest.
: Patients who did not opt out for use of remaining tumor material for research purpose or had giving informed consent for performing additional biopsies for research purposes, were screened for availability of tumor samples after local institutional review board approval (IRBd19-095 and IRBm19-130), in accordance with national privacy and ethics guidelines.